Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030
The Business Research Company’s Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON, UK, April 1, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
Increasing R&D investments and collaborations due to the emerging technologies for treatment is a key trend in Alzheimer’s disease (AD) treatment market. The Alzheimer’s Association is assisting with funds for researchers in search of innovative therapeutic approaches, and seeks more government funding for Alzheimer’s studies. Technologies such as ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market. For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field on their peptidomimetic series.
Manufacturing companies such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, vTv Therapeutics are more focused on R&D investments with their research molecules in the clinical trials to achieve a breakthrough for the treatment of AD.
Other AD market trends include mergers and acquisitions. In January 2020, Biogen Inc., an American multinational biotechnology company, acquired Pfizer Inc. for an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments. Through this acquisition, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). Pfizer Inc. is an American multinational pharmaceutical corporation engaged in the discovery, development and manufacture of healthcare products including medicines and vaccines.
Major players in the global Alzheimer’s disease drugs market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.
Read More On The Global Alzheimer’s Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-treatment-global-market-report-2020-30-covid-19-growth-and-change
The global Alzheimer’s disease treatments market is expected to grow from $3.43 billion in 2020 to $3.76 billion in 2021 at a compound annual growth rate (CAGR) of 9.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global Alzheimer’s disease treatment market is expected to reach $5.91 billion in 2025 at a CAGR of 12%.
The global Alzheimer’s disease market is segmented by drug class into cholinergic, memantine, combined drug, AChE inhibitors, immunoglobulins, by drug type into cholinesterase inhibitors, NMDA receptor antagonists, and by therapeutics into cholinesterase inhibitors, NMDA receptor antagonists, other therapeutics.
Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides Alzheimer’s disease treatment market overview, forecast Alzheimer’s disease treatment market size and growth for the whole market, Alzheimer’s disease treatment market segments, and geographies, Alzheimer’s disease treatment market trends, Alzheimer’s disease treatment market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Alzheimer’s Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3409&type=smp
Here Is A List Of Similar Reports By The Business Research Company:
Central Nervous System Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market-report-2020-30-covid-19-implications-and-growth
Anti-Parkinson Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report-2020-30-covid-19-growth-and-change
Neurodegenerative Disorder Therapeutics Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutics-market-global-report
Interventional Neurology Devices And Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report
Retirement Communities Market – By Type (Continuing Care Retirement Communities, Rest Homes, Assisted Living Facilities, Assisted Living Facilities With Nursing Care), By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/retirement-communities-market
Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Oliver Guirdham
The Business Research Company
20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn
Discussion about this post